- ZK824190
-
- $163.00
-
2026-07-27
- CAS:2254001-81-3
- Purity: 98.84%
- Supply Ability: 10g
- ZK824190
-
- $163.00
-
2026-07-27
- CAS:2254001-81-3
- Purity: 98.84%
- Supply Ability: 10g
|
| | ZK824859 Basic information |
| Product Name: | ZK824859 | | Synonyms: | CS-2839;ZK824859;ZK824859;ZK-824859;ZK 824859;2254001-81-3;ZK824190;Butanoic acid, 2-[[6-[[3'-(aminomethyl)[1,1'-biphenyl]-3-yl]oxy]-3,5-difluoro-2-pyridinyl]oxy]-, (2R)-;Inhibitor,Serine endopeptidases,protease,multiple sclerosis,plasminogen,Urokinase,Plasminogen activator inhibitor-1,Serine,Serine proteases,Ser/Thr Protease,ZK-824190,uPA,Threonine proteases,ZK824190,inhibit,ZK 824190,PAI-1;(R)-2-((6-((3'-(aminomethyl)-[1,1'-biphenyl]-3-yl)oxy)-3,5-difluoropyridin-2-yl)oxy)butanoic acid;ZK824190, 10 mM in DMSO | | CAS: | 2254001-81-3 | | MF: | C22H20F2N2O4 | | MW: | 414.4 | | EINECS: | | | Product Categories: | | | Mol File: | 2254001-81-3.mol |  |
| | ZK824859 Chemical Properties |
| solubility | DMSO: Soluble
Methanol: Soluble |
| | ZK824859 Usage And Synthesis |
| Uses | ZK824190 is an orally available and selective urokinase plasminogen activator (uPA) inhibitor as a potential treatment for multiple sclerosis. IC50s of 237, 1600 and 1850 nM for uPA, tPA, and Plasmin, respectively[1]. | | in vivo | ZK824190 (2mg/kg; PO) exhibits a relatively high oral availability and a moderate half time (T1/2=2.8 h)[1]. | Animal Model: | Rats with experimental autoimmune encephalomyelitis (EAE) model[1] | | Dosage: | 2mg/kg (Pharmacokinetic Analysis) | | Administration: | PO | | Result: | Oral availability F=55%; Cmax=0.64g/mL and AUC=2.2h*g/mL; T1/2=2.8 h. |
| | References | [1] Islam I, et al. Discovery of selective urokinase plasminogen activator (uPA) inhibitors as a potential treatment for multiple sclerosis. Bioorg Med Chem Lett. 2018 Nov 1;28(20):3372-3375. DOI:10.1016/j.bmcl.2018.09.001 |
| | ZK824859 Preparation Products And Raw materials |
|